ICON to partner with US govt agency to test COVID vaccine candidates
Reuters
Published Sep 13, 2023 08:28AM ET
Updated Sep 13, 2023 10:46AM ET
(Reuters) -Contract research firm ICON Plc said on Wednesday it is partnering with the U.S. government for a clinical trial to test the effectiveness of next generation COVID-19 vaccine candidates.
As part of the collaboration with Biomedical Advanced Research and Development Authority, ICON will conduct a mid-stage trial of 10,000 participants to assess the efficacy of a next generation COVID-19 vaccine relative to currently available shots.
The U.S. agency will select the vaccine candidate for the trial.
The trial is part of a $5 billion U.S. government initiative called "Project NextGen", which aims to provide better protection from coronaviruses, including the one that causes COVID-19.
While current vaccines and treatments have been effective, there have been concerns around their durability of protection against a rapidly mutating virus.
The U.S. Food and Drug Administration on Monday authorized updated COVID-19 vaccines from Pfizer/BioNTech and Moderna (NASDAQ:MRNA) that target the XBB.1.5 subvariant of the virus.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.